Please use this identifier to cite or link to this item:
http://nopr.niscpr.res.in/handle/123456789/46030Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Jain, N | - |
| dc.contributor.author | Srivastava, T S | - |
| dc.date.accessioned | 2019-03-18T09:37:41Z | - |
| dc.date.available | 2019-03-18T09:37:41Z | - |
| dc.date.issued | 1992-02 | - |
| dc.identifier.issn | 0975-0975(Online); 0376-4710(Print) | - |
| dc.identifier.uri | http://nopr.niscair.res.in/handle/123456789/46030 | - |
| dc.description | 102-105 | en_US |
| dc.description.abstract | The synthesis of platinum compounds of the type [Pt (daba) X2](where daba = 3,4-diaminobenzoic acid and X = Cl, Br, or I) and the analogous chloro and bromo compounds of Pd(II) has been carried out. These compounds have been characterized by molar conductance measurements, electronic absorption, and infrared, 1H NMR and X-ray photoelectron spectroscopy. The complexes are non-electrolytic in nature and have square planar geometry with two coordination positions occupied by two amino groups of 3,4- diaminobenzoic acid and remaining two positions occupied by halide ions. The sodium salts of the above compounds have been tested against P388 lymphocytic leukemia cells. [Pt(daba)Cl2] and Pt(daba)Br2l have I.D.50 ovalues less than that of cisplatin and [Pt(daba)I2] has I.D50 values comparable to that of cisplatin. | en_US |
| dc.language.iso | en_US | en_US |
| dc.publisher | NISCAIR-CSIR, India | en_US |
| dc.rights | CC Attribution-Noncommercial-No Derivative Works 2.5 India | en_US |
| dc.source | IJC-A Vol.31A(02) [February 1992] | en_US |
| dc.title | Synthesis, characterization and cytotoxicity of (3,4-diaminobenzoic acid)- haloplatinum(II)/palladium(II) | en_US |
| dc.type | Article | en_US |
| Appears in Collections: | IJC-A Vol.31A(02) [February 1992] | |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| IJCA 31A(2) 102-105.pdf | 2.83 MB | Adobe PDF | View/Open |
Items in NOPR are protected by copyright, with all rights reserved, unless otherwise indicated.